Sanofi Reports Results of Zynquista (sotagliflozin) in P-III InSynchrony Program for Type2 Diabetes and Terminates Its Collaboration with Lexicon

 Sanofi Reports Results of Zynquista (sotagliflozin) in P-III InSynchrony Program for Type2 Diabetes and Terminates Its Collaboration with Lexicon

Sanofi Reports Results of Zynquista (sotagliflozin) in P-III InSynchrony Program for Type2 Diabetes and Terminates Its Collaboration with Lexicon

Shots:

  • The three P-III studies (SOTA-MET, SOTA-CKD3, SOTA-CKD4) involves assessing of Zynquista vs PBO in patients with T2D. The first two studies resulted in meeting its 1EPs i.e, @26wks. reduction in HbA1c while SOTA-CKD4 did not demonstrate a reduction in HbA1c
  • Additionally, Sanofi to terminates its development and commercialization agreement with Lexicon for Zynquista in all ongoing global studies for T1D & T2D signed in Nov’2015 following the results of P-III InSynchrony program
  • Zynquista is an oral SGLT1 and SGLT2 inhibitor which are responsible for glucose absorption in GI tract & kidney respectively and has received approval as an adjunct to insulin therapy to improve glycemic control in patients with T1D Mellitus with BMI ≥ 27 kg/m2 in the EU

Click here to­ read full press release/ article | Ref: Sanofi | Image: Wsj

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post